Based on the Shanghai Fosun Pharmaceutical (Group) Co. Ltd stock forecast from 0 analysts, the average analyst target price for Shanghai Fosun Pharmaceutical (Group) Co. Ltd is not available over the next 12 months. Shanghai Fosun Pharmaceutical (Group) Co. Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Shanghai Fosun Pharmaceutical (Group) Co. Ltd is Slightly Bullish , which is based on 4 positive signals and 2 negative signals. At the last closing, Shanghai Fosun Pharmaceutical (Group) Co. Ltd’s stock price was USD 1.53. Shanghai Fosun Pharmaceutical (Group) Co. Ltd’s stock price has changed by +0.00% over the past week, -18.94% over the past month and -48.59% over the last year.
No recent analyst target price found for Shanghai Fosun Pharmaceutical (Group) Co. Ltd
No recent average analyst rating found for Shanghai Fosun Pharmaceutical (Group) Co. Ltd
Company Overview Shanghai Fosun Pharmaceutical (Group) Co. Ltd
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, anti-infection, API's and intermediate, metabolism, alimentary system, cardiovascular and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services, and investment management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China. Read Less
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical D...Read More
Stock Target Advisor's fundamental analysis for Shanghai Fosun Pharmaceutical (Group) Co. Ltd's stock is Slightly Bullish .
SFOSF stock's dividend yield is 3.21%.
Our analysis grades SFOSF stock's dividend yield at C-. This means that SFOSF stock's dividend yield is above 71% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the OTC exchange.
Based on this SFOSF may be a average dividend stock for its sector.
Unfortunately we do not have enough data on SFOSF's stock to indicate what its average analyst target is.
SFOSF stock's Price/Earning ratio is 9.63.
Our analysis grades SFOSF stock's Price / Earning ratio at F. This means that SFOSF stock's Price/Earning ratio is above 44.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the OTC exchange.
Based on this SFOSF may be fairly valued for its sector
The last closing price of SFOSF's stock was USD 1.53.
The most recent market capitalization for SFOSF is USD 8.17B.
Unfortunately we do not have enough analyst data on SFOSF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Shanghai Fosun Pharmaceutical (Group) Co. Ltd's stock.
As per our most recent records Shanghai Fosun Pharmaceutical (Group) Co. Ltd has 38,399 Employees.
Shanghai Fosun Pharmaceutical (Group) Co. Ltd's registered address is Building A, Shanghai, China, 200233.
You can get more information about it from Shanghai Fosun Pharmaceutical (Group) Co. Ltd's website at https://www.fosunpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SFOSF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
